GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Accounts Receivable

MiMedx Group (MiMedx Group) Accounts Receivable : $53.9 Mil (As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. MiMedx Group's accounts receivables for the quarter that ended in Dec. 2023 was $53.9 Mil.

Accounts receivable can be measured by Days Sales Outstanding. MiMedx Group's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 56.61.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. MiMedx Group's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $0.25.


MiMedx Group Accounts Receivable Historical Data

The historical data trend for MiMedx Group's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Accounts Receivable Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 32.33 35.42 40.35 43.08 53.87

MiMedx Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 43.08 44.69 48.96 49.01 53.87

MiMedx Group Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


MiMedx Group Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

MiMedx Group's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=53.871/86.832*91
=56.61

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), MiMedx Group's accounts receivable are only considered to be worth 75% of book value:

MiMedx Group's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(82+0.75 * 53.871+0.5 * 21.021-96.33
-0-0)/146.228
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


MiMedx Group Accounts Receivable Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604

MiMedx Group (MiMedx Group) Headlines

From GuruFocus

MIMEDX Announces Chief Financial Officer Transition

By sperokesalga sperokesalga 03-23-2023

MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer

By Stock market mentor Stock market mentor 01-03-2023